Bladder Cancer

>

Latest News

bladder cancer
Newer Urothelial Cancer Drugs Are Effective But Pricey

December 5th 2023

Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.

FDA
FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

December 4th 2023

Adding Nivolumab to Chemotherapy Improves Survival Rates in Metastatic Urothelial Carcinoma
Adding Nivolumab to Chemotherapy Improves Survival Rates in Metastatic Urothelial Carcinoma

October 23rd 2023

urothelial carcinoma
Enfortumab Vedotin/Pembrolizumab May Be New SOC in Frontline Urothelial Cancer

October 23rd 2023

bladder cancer
Bladder-Sparing Radiotherapy Yields Comparable Survival Outcomes to Radical Cystectomy in Nonmetastatic Node-Positive Bladder Cancer

July 31st 2023

Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.